- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Semaglutide an effective alternative drug option to treat obesity
Obesity is a seriously neglected disease that is factually a multifactorial chronic disease affecting 650 million adults globally. It is associated with a number of physical and mental health complications including risk factors for cardiovascular disease, coronary heart disease, heart failure, hypertension, and atrial fibrillation.
Weight losses of 5% or more of initial weight help to minimize these complications, with larger losses producing greater health benefits. Semaglutide is a glucagon-like peptide-1 receptor agonist that was recently approved by the US Food and Drug Administration for chronic weight management.
Anti-obesity medications (AOM) help facilitate weight management when used with a reduced calorie diet and increased physical activity by individuals with a body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 with an obesity-related co- morbidity such as type 2 diabetes, hypertension, or dyslipidemia. Patients who are unable to achieve weight loss goals with a comprehensive weight loss (e.g., 5% of initial weight loss in 3-6 months) may pursue adjunct treatment with AOM
Weight-loss and cardiometabolic efficacy, and safety of semaglutide was evaluated and 2.4 mg/week for obesity showed greater results. Once-weekly subcutaneous semaglutide 1.0 mg was approved by the US FD FDA in 2017 and the E EMA in 2018 for the treatment of type 2 diabetes. A once-daily oral version of the medication, at a maximum dose of 14 mg, was approved for treating type 2 diabetes in the US in 2019 and in Europe in 2020. The initial dose is 0.25 mg, administered by subcutaneous injection in the abdomen, thigh, or upper arm once weekly for 4 weeks. The dose is increased in 4-week intervals (over a total of 16 weeks) until a dose of 2.4 mg per week is reached.
Semaglutide demonstrated the largest weight loss of any obesity medication to date with reductions of approximately 15% of initial weight at 68 weeks, accompanied by improvements in cardiovascular risks factors and physical functioning. The approval of this medication provides patients with greater options for weight management.
Reference: https://doi.org/10.1016/j.tcm.2021.12.008
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751